ALGS Q4 2024 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$629,000-76.5% YoY

Gross Profit

$629,000100.0% margin

Operating Income

-$21M-3269.2% margin

Net Income

-$82M-13060.4% margin

EPS (Diluted)

$-13.08

QoQ Revenue Growth

-50.4%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$70M

Total Liabilities

$99M

Stockholders' Equity

-$29M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$629,000	$3M	-76.5%
Gross Profit	$629,000	$3M	-76.5%
Operating Income	-$21M	-$26M	+20.9%
Net Income	-$82M	-$28M	-194.5%